A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: No differences in cytogenetic responses

Annals of Hematology

Volumn 82, Issue 12, 2003, Pages 750-758

  Penarrubia M J ^a   Odriozola, J ^b   Gonzalez C ^c   Massague I ^d   Miguel, A ^e   Gonzalez San Miguel J D ^e,f   Perez Encinas M ^g   Lavilla, E ^h   Giraldo, M P ⁱ   Casado, L F ^j   Ferrer, S ^k   Steegmann, J L ^l  

^a HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^f HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^h HOSPITAL XERAL CALDE   (Spain)

ⁱ HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^j HOSPITAL VIRGEN DE LA SALUD   (Spain)

^k HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^l HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

more..

Author keywords

Chronic myeloid leukemia; Cytogenetic response; Dose; Interferon alpha; Randomized clinical trial

Indexed keywords

HYDROXYUREA; RECOMBINANT ALPHA2A INTERFERON;

ADULT; ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL DISEASE; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; HYPOTHYROIDISM; KARYOTYPING; LIVER DISEASE; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MULTICENTER STUDY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SKIN DISEASE; SPAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; CYTOGENETIC ANALYSIS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; LEUKOCYTE COUNT; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 18344413590     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-003-0724-z     Document Type: Article

References (23)

1. Alimena G, Morra E, Lazzarino M, Liberati AM, Montefusco E, Inverardi D, Bernasconi P, Mancini M, Donti E, Grignani F (1988) Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood 72:642-647
2. Allan NC, Richards SM, Shepherd PC (1995) UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 345:1392-1397
3. Baccarani M, Russo D, Rosti G, Martinelli G (2003) Interferon-alfa for chronic myeloid leukemia. Sernin Hematol 40:22-33
4. Benelux CML Study Group (1998) Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha 2b for chronic myeloid leukemia. The Benelux CML Study Group. Blood 91:2713-2721
5. Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilbot J, Trabacchi E, Hehlmann R, Hochhaus A, Shepherd PC, Steegmann JL, Kluin-Nelemans HC, Thaler J, Simonsson B, Louwagie A, Reiffers J, Mahon FX, Montefusco E, Alimena G, Hasford J, Richards S, Saglio G, Testoni N, Martinelli G, Tura S, Baccarani M (2001) Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 98:3074-3081
6. Chronic Myeloid Leukemia Trialists Collaborative Group (1997) Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. J Natl Cancer Inst 89:1616-1620
7. Faderl S, Talpaz M, Estrov Z, Kantarjian HM (1999) Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 131:207-219
8. Hasford J, Baccarani M, Hehlmann R, Anseri H, Tura S, Zuffa E (1996) Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-alpha. Blood 87:5384-5391
9. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL, Ansari H (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90:850-858
10. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Loffler H, Hochhaus A, Heinze B (1994) Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 84:4064-4077
11. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R (2002) Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16:2190-2196
12. Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994) Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N Engl J Med 330:820-825
13. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M (1995) Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med 122:254-261
14. Kantarjian HM, Talpaz M (1998) Questions raised by the Benelux CML Study Group: results from the randomized study with hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha2b for chronic myeloid leukemia. Blood 92:2984-2987
15. Mahon FX, Faberes C, Montastruc M, Si-Mour S, Boiron JM, Marit G, Bilhou-Nabera C, Cony-Makhoul P, Pigneux A, Bernard P, Broustet A, Reiffers J (1996) High response rate using recombinant interferon-alpha in patients with newly diagnosed chronic myeloid leukemia. Bone Marrow Transplant 17 [Suppl 3]:S33-S37
16. Mahon FX, Faberes C, Pueyo S, Cony-Makhoul P, Salmi R, Boiron JM, Marit G, Bilhou-Nabera C, Carrere A, Montastruc M, Pigneux A, Bernard P, Reiffers J (1998) Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-alpha. Blood 92:4059-4065
17. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004
18. Ohnishi K, Ohno R, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, Dohy H, Mizoguchi H, Miyawaki S, Tsubaki K (1995) A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 86:906-916
19. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F (1984) Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 63:789-799
20. Steegmann JL, Odriozola J, Rodriguez-Salvanes F, Giraldo P, Garcia-Larana J, Ferro MT, Benitez E, Perez-Pons C, Giralt M, Escribano L, Lavilla E, Miguel A, Areal C, Perez-Encinas M, Abad A, Maldonado J, Massague I, Fernandez-Ranada JM (1999) Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML. Haematologica 84:978-987
21. Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock R (1994) Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J Clin Invest 94:1383-1389
22. Talpaz M, Kantarjian HM, O'Brien S, Kurzrock R (1997) The M.D. Anderson Cancer Center experience with interferon-alpha therapy in chronic myelogenous leukaemia. Baillieres Clin Haematol 10:291-305
23. Talpaz M, McCredie KB, Mavligit GM, Gutterman JU (1983) Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 62:689-692